In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

The company plans to begin enrolling the trial next quarter across eight US sites to test the vaccine as a monotherapy and in combination with Keytruda.

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

Chemotherapy exerts systemic effects that extend beyond direct tumor cell killing, according to a new study led by Tatiana Petrova, professor at the Faculty of Biology and Medicine at the University ...

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...

The SFDA is the first regulatory authority globally to grant conditional approval for this medication for the treatment of NSCLC ...